Chemokine markers predict biochemical recurrence of prostate cancer following prostatectomy

Clinical Cancer Research

Volumn 14, Issue 23, 2008, Pages 7790-7797

  Blum, David L ^a   Koyama, Tatsuki ^a   M'Koma, Amosy E ^a   Iturregui, Juan M ^a   Martinez Ferrer, Magaly ^a   Uwamariya, Consolate ^a   Smith, Joseph A ^a   Clark, Peter E ^a   Bhowmick, Neil A ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FRACTALKINE; INTERLEUKIN 15; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; SEMINAL VESICLE; SENSITIVITY AND SPECIFICITY; ADENOCARCINOMA; AREA UNDER THE CURVE; BIOSYNTHESIS; CASE CONTROL STUDY; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; ROC CURVE; TUMOR RECURRENCE;

ADENOCARCINOMA; AGED; AREA UNDER CURVE; CASE-CONTROL STUDIES; CHEMOKINE CCL4; CHEMOKINE CX3CL1; HUMANS; INTERLEUKIN-15; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 59449091206     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1716     Document Type: Article

References (37)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
2. Thompson KE, Hernandez J, Canby-Hagino ED, Troyer D, Thompson IM. Prognostic features in men who died of prostate cancer. J Urol 2005;174: 553-6; discussion 6.
3. Glode LM. The case for adjuvant therapy for prostate cancer. J Urol 2006;176:S30-3.
4. Gomella LG, Zeltser I, Valicenti RK. Use of neoadjuvant and adjuvant therapy to prevent or delay recurrence of prostate cancer in patients undergoing surgical treatment for prostate cancer. Urology 2003; 62 Suppl 1:46 -54.
5. Akduman B, Crawford ED. The management of high risk prostate cancer. J Urol 2003;169:1993-8.
6. Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005;294:433-9.
7. Stephenson AJ, Scardino PT, Eastham JA, et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2005;23:7005-12.
8. Kakinuma T, Hwang ST. Chemokines, chemokine receptors, and cancer metastasis. J Leukoc Biol 2006; 79:639-51.
9. Tenta R, Sotiriou E, Pitulis N, Thyphronitis G, Koutsilieris M. Prostate cancer cell survival pathways activated by bone metastasis microenvironment. J Musculoskelet Neuronal Interact 2005;5:135 -44.
10. Karin M. Nuclear factor-κB in cancer development and progression. Nature 2006;441:431 -6.
11. Luo J L, Tan W, Ricono JM, et al. Nuclear cytokine- activated IKKκ controls prostate cancer metastasis by repressing maspin. Nature 2007;446:690-4.
12. Pencina MJ, DAgostino RB, Sr., DAgostino RB, Jr., Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008;27:157 -72; discussion 207 -12.
13. Schoenfeld DA. Sample-size formula for theproportional-hazards regression model. Biometrics1983;39: 499-503.
14. Foundation for Statistical Computing. Alanguage and environment for statistical computing. Vienna (Austria); 2008.
15. Wu JD, Higgins LM, Steinle A, Cosman D, Haugk K, Plymate SR. Prevalent expression of the immunosti- mulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J Clin Invest 2004;114:560-8.
16. Jamieson WL, Shimizu S, DAmbrosio JA, Meucci O, Fatatis A. CX3CR1 is expressed by prostate epithelial cells and androgens regulate the levels of CX3CL1/fractalkine in the bone marrow: potential role in prostate cancer bone tropism. Cancer Res 2008;68:1715-22.
17. Wang H, Thompson TC. Gene-modified bonemarrow cell therapy for prostate cancer. Gene Ther 2008;15: 787-96.
18. Takeshi U, Sadar MD, Suzuki H, et al. Interleukin-4in patients with prostate cancer. Anticancer Res 2005; 25:4595 -8.
19. Lee SO, Pinder E, Chun JY, Lou W, Sun M, Gao AC. Interleukin-4 stimulates androgen-independent growth in LNCa P human prostate cancer cells. Prostate 2008;68:85 -91.
20. Grambsch P,Therneau T. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika1994;81:515 -26.
21. DAmico AV, Whittington R, Malkowicz SB, et al. Combination of the preoperative PSA level, biopsy Gleason score, percentage of positive biopsies, and MRI T-stage to predict early PSA failure in men with clinically localized prostate cancer. Urology 2000;55: 572-7.
22. Kattan MW. Nomograms are superior to staging and risk grouping systems for identifying high-risk patients: preoperative application in prostate cancer. Curr Opin Urol 2003;13:111 -6.
23. Chun FK, Steuber T, Erbersdobler A, et al. Development and internal validation ofa nomogram predicting the probability of prostate cancer Gleason sum upgrading between biopsy and radical prostatectomy pathology. Eur Urol 2006;49:820-6.
24. Bolla M, van Poppel H, Collette L, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005;366:572 -8.
25. Thompson IM, Jr., Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 2006;296:2329-35.
26. Bottke D, Wiegel T. Adjuvant radiotherapy after radical prostatectomy: indications, results and side effects. Urol Int 2007;78:193-7.
27. Morgan SC, Waldron TS, Eapen L, Mayhew LA, Winquist E, Lukka H. Adjuvant radiotherapy following radical prostatectomy for pathologicT3or margin-positive prostate cancer: a systematic review and meta-analysis. Radiother Oncol 2008;88:1 -9.
28. Akashi T, Koizumi K, Nagakawa O, Fuse H, SaikiI. Androgen receptor negatively influences the expression of chemokine receptors (CXCR4, CCR1) and ligand-mediated migration in prostate cancer DU-145. Oncol Rep 2006;16:831 -6.
29. Shulby SA, Dolloff NG, Stearns ME, Meucci O, Fatatis A. CX3CR1-fractalkine expression regulates cellular mechanisms involved in adhesion, migration, and survival of human prostate cancer cells. Cancer Res 2004;64:4693-8.
30. Suzuki K, Nakazato H, Matsui H, et al. NK cell-mediated anti-tumor immune response to human prostate cancer cell, PC-3: immunogene therapy using a highly secretable form of interleukin-15 gene transfer. J Leukoc Biol 2001;69:531 -7.
31. GonzalezCM,Roehl KA, AntenorJV,BluntLW,Han M, Catalona WJ. Preoperative PSA level significantly associated with interval to biochemical progression after radical retropubic prostatectomy. Urology 2004; 64:723-8.
32. Henshall SM, Horvath LG, Quinn DI, et al. Zinc-α2- glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy. J Natl Cancer Inst 2006;98:1420-4.
33. Jayachandran J, Banez LL, Levy DE, et al. Risk stratification for biochemical recurrence in men with positive surgical margins or extracapsular disease after radical prostatectomy: results from the SE ARCH database. J Urol 2008;179:1791 -6; discussion 6.
34. Paris PL, Weinberg V, Simko J, et al. Preliminaryevaluation of prostate cancer metastatic risk biomarkers. Int J Biol Markers 2005;20:141 -5.
35. Schmidt H, DeAngelis G, Eltze E, Gockel I,Semjonow A, Brandt B. Asynchronous growth of prostate cancer is reflected by circulating tumor cells delivered from distinct, even small foci, harboring loss of heterozygosity of the PTEN gene. Cancer Res 2006;66:8959-65.
36. Simmons MN, Stephenson AJ, Klein EA. Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy. Eur Urol 2007;51:1175 -84.
37. Ward JF, Zincke H, Bergstralh EJ, Slezak JM, Blute ML. Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy. J Urol 2004; 172:2244-8.